FDA Grants Full Approval to Tecartus for Relapsed Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) granted full approval to Tecartus, a CAR T-cell therapy, for adults with relapsed or refractory mantle cell lymphoma (MCL) on April 2, 2026. The approval covers patients whose disease has returned or stopped responding to prior treatments, including BTK inhibitors.
The decision is based on longer-term follow-up from the ZUMA-2 clinical trial, which showed that Tecartus can produce deep and durable remissions in patients with heavily pretreated MCL. In the study, the overall response rate was 91%, meaning most patients experienced meaningful tumor reduction, while 68% achieved a complete response, meaning no detectable lymphoma remained after treatment.
For the MCL community, this is a significant development because treatment options become more limited once the disease progresses after BTK inhibitors.
What Tecartus Is
Tecartus is a personalized CAR T-cell therapy. Doctors collect a patient’s own T cells — immune cells that help fight disease — and genetically modify them in a laboratory so they can recognize and attack mantle cell lymphoma cells. The engineered cells are then infused back into the patient to help the immune system target the cancer directly.
Unlike traditional chemotherapy, which attacks rapidly dividing cells broadly, CAR T-cell therapy is designed to create a more targeted immune response against the lymphoma.
Why This Approval Matters
Tecartus first received accelerated approval several years ago based on early clinical data. This new full approval is important because it confirms that the responses seen initially were not only strong, but also durable over time.
Updated trial results showed that many patients maintained remission years after treatment, including some with high-risk disease characteristics that are traditionally harder to treat. For patients whose lymphoma has relapsed after multiple prior therapies, this offers renewed hope for longer-lasting disease control.
The approval also reflects the growing role of cellular therapies in blood cancers. While CAR T-cell therapy is still a complex treatment delivered at specialized centers, Tecartus has now become an established option for patients with relapsed or refractory MCL who previously had relatively few effective long-term treatment choices.
Sources
- Oncology News Central — FDA Fully Approves Brexucabtagene Autoleucel for Mantle Cell Lymphoma
- AJMC — FDA Approves Brexucabtagene Autoleucel for Refractory Mantle Cell Lymphoma
- Cancer Network — FDA Approves Brexucabtagene Autoleucel in Adult R/R MCL
- Targeted Oncology — FDA Grants Full Approval to Brexu-cel in R/R Mantle Cell Lymphoma